Suppr超能文献

套细胞淋巴瘤细胞高表达CXCR4、CXCR5和VLA-4(CD49d):对与基质微环境相互作用及特异性靶向的重要性。

Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.

作者信息

Kurtova Antonina V, Tamayo Archito T, Ford Richard J, Burger Jan A

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1402, USA.

出版信息

Blood. 2009 May 7;113(19):4604-13. doi: 10.1182/blood-2008-10-185827. Epub 2009 Feb 19.

Abstract

Mantle cell lymphoma (MCL) is characterized by an early, widespread dissemination and residual disease after conventional treatment, but the mechanisms responsible for lymphoma cell motility and drug resistance are largely unknown. There is growing evidence suggesting that chemokine receptors and adhesion molecules are critical for malignant B-cell trafficking and homing to supportive tissue microenvironments, where they receive survival and drug resistance signals. Therefore, we examined chemokine receptor and adhesion molecule expression and function in MCL cells and their importance for migration and adhesion to marrow stromal cells (MSCs). We found that MCL cells display high levels of functional CXCR4 and CXCR5 chemokine receptors and VLA-4 adhesion molecules. We also report that MCL cells adhere and spontaneously migrate beneath MSCs in a CXCR4- and VLA-4-dependent fashion (pseudoemperipolesis). Moreover, we demonstrate that MSCs confer drug resistance to MCL cells, particularly to MCL cells that migrate beneath MSC. To target MCL-MSC interactions, we tested Plerixafor, a CXCR4 antagonist, and natalizumab, a VLA-4 antibody. Both agents blocked functional responses to the respective ligands and inhibited adhesive interactions between MCL cells and MSCs. These findings provide a rationale to further investigate the therapeutic potential of these drugs in MCL.

摘要

套细胞淋巴瘤(MCL)的特征是早期广泛播散以及传统治疗后出现残留病灶,但淋巴瘤细胞迁移和耐药的机制在很大程度上尚不清楚。越来越多的证据表明,趋化因子受体和黏附分子对恶性B细胞的转运以及归巢至支持性组织微环境至关重要,在这些微环境中,它们会接收到生存和耐药信号。因此,我们检测了趋化因子受体和黏附分子在MCL细胞中的表达及功能,以及它们对迁移和黏附于骨髓基质细胞(MSC)的重要性。我们发现MCL细胞高水平表达功能性趋化因子受体CXCR4和CXCR5以及黏附分子VLA-4。我们还报告称,MCL细胞以依赖CXCR4和VLA-4的方式(假包绕现象)黏附并自发迁移至MSC下方。此外,我们证明MSC赋予MCL细胞耐药性,尤其是赋予迁移至MSC下方的MCL细胞。为了靶向MCL-MSC相互作用,我们测试了CXCR4拮抗剂普乐沙福以及VLA-4抗体那他珠单抗。这两种药物均阻断了对各自配体的功能性反应,并抑制了MCL细胞与MSC之间的黏附相互作用。这些发现为进一步研究这些药物在MCL中的治疗潜力提供了理论依据。

相似文献

4
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.
Blood. 2008 Jul 1;112(1):150-8. doi: 10.1182/blood-2007-12-129395. Epub 2008 Apr 30.
7
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
Blood. 2017 Jul 27;130(4):501-513. doi: 10.1182/blood-2017-04-776740. Epub 2017 May 22.

引用本文的文献

2
CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment.
Biomolecules. 2025 May 13;15(5):716. doi: 10.3390/biom15050716.
4
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?
Cancers (Basel). 2024 Dec 29;17(1):72. doi: 10.3390/cancers17010072.
7
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.
Blood Adv. 2024 Aug 27;8(16):4370-4385. doi: 10.1182/bloodadvances.2023012039.
8
Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).
Cell Commun Signal. 2024 Mar 12;22(1):177. doi: 10.1186/s12964-024-01544-7.
9
Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies.
Front Cell Dev Biol. 2023 Oct 31;11:1270398. doi: 10.3389/fcell.2023.1270398. eCollection 2023.
10
Chronic Lymphocytic Leukemia: Disease Biology.
Acta Haematol. 2024;147(1):8-21. doi: 10.1159/000533610. Epub 2023 Sep 16.

本文引用的文献

1
Stromal gene signatures in large-B-cell lymphomas.
N Engl J Med. 2008 Nov 27;359(22):2313-23. doi: 10.1056/NEJMoa0802885.
2
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.
Leukemia. 2009 Jan;23(1):43-52. doi: 10.1038/leu.2008.299. Epub 2008 Nov 6.
4
Stem cells and niches: mechanisms that promote stem cell maintenance throughout life.
Cell. 2008 Feb 22;132(4):598-611. doi: 10.1016/j.cell.2008.01.038.
7
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.
Blood. 2008 Apr 1;111(7):3893-5. doi: 10.1182/blood-2007-10-120329. Epub 2008 Jan 30.
9
Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling.
Blood. 2008 May 1;111(9):4764-70. doi: 10.1182/blood-2007-10-115915. Epub 2008 Jan 3.
10
Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways.
Hematology Am Soc Hematol Educ Program. 2007:270-6. doi: 10.1182/asheducation-2007.1.270.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验